Analysts Set Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Price Target at $13.00

Shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) have received a consensus rating of “Moderate Buy” from the seven brokerages that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $13.00.

Several research firms have recently commented on OBIO. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Orchestra BioMed in a research report on Thursday, May 14th. Wall Street Zen lowered shares of Orchestra BioMed from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Piper Sandler reaffirmed an “overweight” rating and issued a $10.00 price target (up from $9.00) on shares of Orchestra BioMed in a research report on Tuesday, August 11th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Orchestra BioMed in a research report on Friday, July 17th. Finally, Barclays upped their target price on shares of Orchestra BioMed from $12.00 to $13.00 and gave the company an “overweight” rating in a research note on Wednesday, May 13th.

Insider Transactions at Orchestra BioMed

In other Orchestra BioMed news, insider Darren Sherman sold 15,000 shares of the business’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $4.09, for a total transaction of $61,350.00. Following the completion of the sale, the insider directly owned 1,154,327 shares in the company, valued at $4,721,197.43. The trade was a 1.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 7.50% of the company’s stock.

Institutional Trading of Orchestra BioMed

Large investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. bought a new position in Orchestra BioMed in the fourth quarter worth approximately $38,000. Creative Planning bought a new stake in shares of Orchestra BioMed during the 2nd quarter valued at $40,000. XTX Topco Ltd bought a new stake in shares of Orchestra BioMed during the 2nd quarter valued at $45,000. Jane Street Group LLC purchased a new stake in shares of Orchestra BioMed in the 2nd quarter worth $50,000. Finally, Virtu Financial LLC purchased a new stake in shares of Orchestra BioMed in the 4th quarter worth $57,000. 53.20% of the stock is currently owned by institutional investors.

Orchestra BioMed Stock Performance

NASDAQ:OBIO opened at $5.43 on Friday. The business has a 50 day moving average price of $4.13 and a 200-day moving average price of $4.16. The firm has a market cap of $326.34 million, a PE ratio of -6.39 and a beta of 0.50. The company has a debt-to-equity ratio of 1.80, a quick ratio of 8.24 and a current ratio of 8.26. Orchestra BioMed has a fifty-two week low of $2.20 and a fifty-two week high of $5.78.

Orchestra BioMed (NASDAQ:OBIO) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.01. The firm had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.14 million. Orchestra BioMed had a negative return on equity of 149.61% and a negative net margin of 184.60%. Equities research analysts predict that Orchestra BioMed will post -1.53 earnings per share for the current year.

About Orchestra BioMed

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.